ストックスクリーナーアプリを入手
89.24
2.28%
1.99
アフターアワーズ：
89.00
-0.24
-0.27%
前日終値:
$87.25
開ける：
$86.84
24時間の取引高:
254.43K
Relative Volume:
0.62
時価総額：
$4.24B
収益：
$291.49M
当期純損益:
$-308.55M
株価収益率:
-19.70
EPS:
-4.53
ネットキャッシュフロー:
$-168.02M
1週間 パフォーマンス:
-1.23%
1か月 パフォーマンス:
+3.06%
6か月 パフォーマンス:
+19.30%
1年 パフォーマンス:
+37.00%
1日の値動き範囲:
$86.06
$89.42
1週間の範囲:
$86.06
$91.10
52週間の値動き範囲:
$55.02
$98.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
名前
Axsome Therapeutics Inc
セクター
電話
(212) 332-3241
住所
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-03 | 開始されました | Wells Fargo | Overweight |
| 2024-08-06 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-04-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2024-01-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-08-08 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 開始されました | Piper Sandler | Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2022-09-07 | 再開されました | Mizuho | Buy |
| 2021-08-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 開始されました | Berenberg | Buy |
| 2021-01-08 | 開始されました | Jefferies | Buy |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-09-29 | 開始されました | BofA Securities | Underperform |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-14 | 開始されました | Cowen | Outperform |
| 2019-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-16 | 繰り返されました | Guggenheim | Buy |
| 2019-10-16 | 開始されました | Guggenheim | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-28 | 開始されました | SunTrust | Buy |
| 2019-05-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-08 | 開始されました | SVB Leerink | Outperform |
| 2019-03-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2015-12-15 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Axsome Therapeutics Inc (AXSM) 最新ニュース
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Sells 29,486 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
(AXSM) Trading Advice - Stock Traders Daily
Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR
Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Major Depressive Disorder Market Expected to Experience Major - openPR
Axsome Therapeutics Presents Data from Multiple Programs - GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - Yahoo Finance
Axsome to Showcase Solriamfetol Research on Daytime Sleepiness and Cognition in OSA and Narcolepsy - Sleep Review
Values First Advisors Inc. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Hennion & Walsh Asset Management Inc. Has $5.23 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Zacks Research Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Learn to Evaluate (AXSM) using the Charts - Stock Traders Daily
3 Bargain Stocks to Buy in a Market That's Priced for Perfection - sharewise
3 Bargain Stocks to Buy in a Market That's Priced for Perfection - The Motley Fool
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Axsome: AXS-07 And Its Upcoming Second PDUFA (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 - The Manila Times
AQR Capital Management LLC Sells 15,440 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition? - Yahoo Finance
SG Americas Securities LLC Makes New $1.04 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Technical Pivots with Risk Controls - Stock Traders Daily
Mizuho maintains Outperform rating on Axsome Therapeutics shares - Investing.com
Mizuho maintains Outperform rating on Axsome Therapeutics shares By Investing.com - Investing.com Australia
Bank of Montreal Can Takes $849,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $124.64 Average Target Price from Analysts - MarketBeat
Clearbridge Investments LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 3.1%Should You Sell? - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $131.00 Price Target at Royal Bank of Canada - MarketBeat
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - Simply Wall St
Axsome Therapeutics (NASDAQ:AXSM) Trading 4.9% Higher - MarketBeat
Axsome Therapeutics amends loan agreement, expands covenants By Investing.com - Investing.com Australia
Axsome Therapeutics amends loan agreement, expands covenants - Investing.com India
Millennium Management LLC Grows Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome to Present Data on AXS-12 and Solriamfetol at Sleep Europe 2024 - Sleep Review
Perceptive Advisors LLC Trims Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up - MSN
1 Under-the-Radar Biotech Stock to Buy and Hold - sharewise
When (AXSM) Moves Investors should Listen - Stock Traders Daily
Wall Street SWOT: Axsome stock fortified by robust IP and CNS market potential - Investing.com
Ford Motor Company (F-N) QuotePress Release - The Globe and Mail
Point72 Europe London LLP Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Affinity Asset Advisors LLC - MarketBeat
AxoGen (NASDAQ:AXGN) Upgraded by StockNews.com to Buy - Defense World
Upward Trajectory: Aquestive Therapeutics Inc (AQST) Posts a Slidee, Closing at 4.88 - The Dwinnex
First Light Asset Management LLC Purchases 2,578,147 Shares of AxoGen, Inc. (NASDAQ:AXGN) - MarketBeat
Axsome Therapeutics Inc (AXSM) 財務データ
収益
当期純利益
現金流量
EPS
Axsome Therapeutics Inc (AXSM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):